Effects of statin therapy on chronic kidney disease patients with coronary artery disease
Related Experiment Video
Updated: Feb 11, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Hao Shen1, Xiaodong Chen2, Jingfen Lu3
1Department of Clinical Laboratory Medicine, First People's Hospital of Wujiang District, Nantong University, Suzhou, China. shenhaojyk@126.com.
Insights
Long-term statin therapy significantly reduced cardiovascular events and mortality in patients with chronic kidney disease (CKD) and coronary artery disease (CAD). However, statins did not benefit CKD-only patients, suggesting tailored treatment approaches are needed.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Long-term statin therapy is known to reduce mortality and offer renoprotective effects in patients with chronic kidney disease (CKD).
- Limited data exists from China regarding the efficacy of statin therapy in patients with both CKD and coronary artery disease (CAD).
- Understanding statin's impact in CKD patients, with or without CAD, is crucial for optimizing cardiovascular and renal outcomes.
Purpose of the Study:
- To compare the long-term effects of statin therapy on cardiovascular events, all-cause death, and cardiac death in 254 CKD patients.
- To investigate the differential impact of statins in CKD patients stratified by the presence or absence of concomitant CAD.
- To provide evidence-based insights into statin use for CKD patients in the Chinese population.
Main Methods:
- A comparative study involving 254 CKD patients, followed for 4 years.
- Patients were analyzed based on the presence (CKD+CAD) or absence (CKD-only) of coronary artery disease.
- Outcomes assessed included cardiovascular events, all-cause mortality, and cardiac mortality.
Main Results:
- Long-term statin therapy demonstrated significantly greater efficacy in CKD+CAD patients, reducing cardiovascular events by 22.2% (P=0.012).
- In CKD+CAD patients, statins led to a substantial reduction in all-cause and cardiac deaths by approximately 28.1% (P<0.001).
- Conversely, statin therapy showed no significant impact on the clinical outcomes of CKD-only patients.
Conclusions:
- Long-term statin therapy markedly decreases cardiovascular events and mortality in CKD patients who also have CAD.
- CKD patients without concomitant CAD exhibited a favorable prognosis and did not appear to benefit from statin treatment.
- Findings suggest that statin therapy should be considered primarily for CKD patients with established CAD.
Background:
Long-term persistence of statin therapy provided an ongoing reduction in mortality among patients with and without a known history of CVD, and renoprotective effect on CKD patients. Until now, very few reports are available from China to address the effects of statin therapy in CKD + CAD patients.
Methods:
We compared the effects of long-term statin therapy (follow-up time 4 years) in terms of cardiovascular events, all-cause death, and cardiac death among 254 CKD patients with or without CAD.
Results:
Long-term statin therapy was much more effective in the CKD + CAD patients compared with CKD patients. In the CAD + CKD patients, long-term statins showed a 22.2% reduction in the CVs rate (P = 0.012). With regard to the all-cause and cardiac deaths, long-term statins had significant treatment effects on the CAD + CKD patients (reduction of about 28.1% in mortality rates, P < 0.001). In contrast, long-term statin therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.
Conclusion:
Long-term statin therapy more dramatically reduced the CVs and mortality rates of the CKD patients with concomitant CAD. In contrast, CKD-only patients had a good prognosis and did not appear to require statin treatment.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:25Chronic Kidney Disease I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:30Coronary Artery Disease III: Clinical Manifestations